VANDA PHARMACEUTICALS INC. License and Services Revenue (Deprecated 2018-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) reported License and Services Revenue (Deprecated 2018-01-31) of $6.75 million for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-08.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2013-11-08
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-09-30 was $6.75M, a 0.00% change year-over-year.
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-06-30 was $6.68M, a 0.00% change year-over-year.
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-03-31 was $6.61M, a 0.00% change year-over-year.
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2012-12-31 was $6.75M, a 0.00% change year-over-year.
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for fiscal 2012 was $26.79M, a 0.00% change from fiscal 2011.
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for fiscal 2011 was $26.79M, a 0.00% change from fiscal 2010.
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for fiscal 2010 was $26.79M, a 942.78% increase from fiscal 2009.
- VANDA PHARMACEUTICALS INC. license and services revenue (deprecated 2018-01-31) for fiscal 2009 was $2.57M.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2013-09-30 | $6.75M 10-Q · filed 2013-11-08 | $13.43M derived: sum of 2 quarters · filed 2013-11-08 | $20.04M 10-Q · filed 2013-11-08 | $26.79M derived: sum of 4 quarters · filed 2013-11-08 |
| 2013-06-30 | $6.68M 10-Q · filed 2013-07-31 | $13.28M 10-Q · filed 2013-07-31 | $20.04M derived: sum of 3 quarters · filed 2013-07-31 | $26.79M derived: sum of 4 quarters · filed 2013-11-08 |
| 2013-03-31 | $6.61M 10-Q · filed 2013-05-10 | $13.36M derived: sum of 2 quarters · filed 2013-05-10 | $20.11M derived: sum of 3 quarters · filed 2013-11-08 | $26.79M derived: sum of 4 quarters · filed 2013-11-08 |
| 2012-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $13.51M derived: sum of 2 quarters · filed 2013-11-08 | $20.18M derived: sum of 3 quarters · filed 2013-11-08 | $26.79M 10-K · filed 2013-02-26 |
| 2012-09-30 | $6.75M 10-Q · filed 2013-11-08 | $13.43M derived: sum of 2 quarters · filed 2013-11-08 | $20.04M 10-Q · filed 2013-11-08 | $26.79M derived: sum of 4 quarters · filed 2013-11-08 |
| 2012-06-30 | $6.68M 10-Q · filed 2013-07-31 | $13.28M 10-Q · filed 2013-07-31 | $20.04M derived: sum of 3 quarters · filed 2013-07-31 | $26.79M derived: sum of 4 quarters · filed 2013-07-31 |
| 2012-03-31 | $6.61M 10-Q · filed 2013-05-10 | $13.36M derived: sum of 2 quarters · filed 2013-05-10 | $20.11M derived: sum of 3 quarters · filed 2013-05-10 | $26.79M derived: sum of 4 quarters · filed 2013-05-10 |
| 2011-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $13.51M derived: sum of 2 quarters · filed 2013-02-26 | $20.18M derived: sum of 3 quarters · filed 2013-02-26 | $26.79M 10-K · filed 2013-02-26 |
| 2011-09-30 | $6.75M 10-Q · filed 2012-11-08 | $13.43M derived: sum of 2 quarters · filed 2012-11-08 | $20.04M 10-Q · filed 2012-11-08 | $26.79M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $6.68M 10-Q · filed 2012-08-03 | $13.28M 10-Q · filed 2012-08-03 | $20.04M derived: sum of 3 quarters · filed 2013-02-26 | $26.79M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $6.61M 10-Q · filed 2012-05-09 | $13.36M derived: sum of 2 quarters · filed 2013-02-26 | $20.11M derived: sum of 3 quarters · filed 2013-02-26 | $26.79M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $13.51M derived: sum of 2 quarters · filed 2013-02-26 | $20.18M derived: sum of 3 quarters · filed 2013-02-26 | $26.79M 10-K · filed 2013-02-26 |
| 2010-09-30 | $6.75M 10-Q · filed 2011-11-07 | $13.43M derived: sum of 2 quarters · filed 2011-11-07 | $20.04M 10-Q · filed 2011-11-07 | |
| 2010-06-30 | $6.68M 10-Q · filed 2011-08-05 | $13.28M 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $2.57M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |